SPECIAL

Referenzen

van Vollenhoven RF et al. Tofacitinib or adalimumab vs placebo in rheumatoid arthritis. N. Engl. J. Med. 2012;367(6):508–19.
van der Heijde D et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559–70.
Kremer J et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis − a randomized trial. Ann Intern Med. 2013;159:253–61.
Fleischmann R et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 2012;367(6):495–507.
Burmester GR et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451–60.
www.swissmedicinfo.ch.
Feist E et al. Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2013;52(8):1352–7.

a Satelliten-Symposium am SGR Kongress, Lausanne: «Xeljanz^® (Tofacitinib citrate) experiences – from clinical trials to real life experiences in the treatment of MTX-IR rheumatoid arthritis patients», 10. September 2015, Lausanne, Veranstalter: Pfizer.

b ORAL: Oral Rheumatoid Arthritis phase 3 triaLs

c ACR20: American College of Rheumatology scale (20%ige Verbesserung)

d DAS28-4(ESR): Disease Activity Score for 28-joint counts based on the Erythrocyte Sedimentation Rate

Impressum

Redaktion:
H+O communications Ltd.
www.hando.ch

Unterstützt von Pfizer AG, Zürich